The Effectiveness of Shimbuto and Ninjinto Japanese Kampo Herbal Medicines in combination with Pegylated interferon alpha plus ribavirin for patients with chronic hepatitis C A pilot study

The Effectiveness of Shimbuto and Ninjinto Japanese Kampo Herbal Medicines in combination with Pegylated interferon alpha plus ribavirin for patients with chronic hepatitis C A pilot study - Shimbuto and Ninjinto, Pegylated alpha Interferon plus ribavirin

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007068

Enrollment

Registered

2012-01-15

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

Patients are randomly devided into two groups combination treatment of pegylated interferon alpha(1.5 microg/kg/week)and ribavirin(600-1000mg/day) with extract of Shimbuto and Ninjinto(15g/day) or not

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All were positive for antibody to HCV and HCV RNA for over 6 months

Exclusion criteria

Exclusion criteria: Exclusion criteria are follows 1)concomitant liver disease (hepatitis B surface antigen positive or Human immunodeficiency virus positive) 2)clinical or biochemical evidence of hepatic decompensation, advanced cirrhosis 3)excessive active alcohol consumption>60g/day or drug abuse 4)evidence of hepatocellula carcinoma 5) antiviral or immunosuppressive treatment within 12 months prior to enrollment

Design outcomes

Primary

Measure	Time frame
VIrological response rate by Abbott RealTime PCR	—

Countries

Japan

Contacts

Public ContactMosaburo Kainuma

Kyushu University Hospital Department of General Internal Medicine

092-642-5909

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026